论文部分内容阅读
目的:探讨联合检测血清和胸水中四种肿瘤标记物对肺癌的诊断意义。方法:采用化学发光和电发光法对60例肺非癌病人和52例肺癌病人血清和胸水的癌胚抗原(CEA)、糖类抗原125(CA125)、细胞角蛋白片段19(CYFRA21-1)和神经原特异性烯醇化酶(NSE)水平进行检测。结果:肺癌患者胸水中CEA为237.4±209.1 ng/ml,CA125为234.0±154.1 U/ml,NSE为38.4±26.5 ng/ml,CYFRA21-1为64.7±61.8 ng/ml,显著高于本组血清(P<0.01)和非肺癌疾病组的血清和胸水中的水平(P<0.01)。胸水中四项联检对肺癌的敏感性达96.6%,而对应的血清中四项联检对肺癌的敏感性则为92.3%。结论:联合检测血清和胸水中CEA、CA125、NSE和CYFRA21-1对肺癌的诊断具有重要意义。
Objective: To explore the diagnostic value of four kinds of tumor markers in serum and pleural effusion for the diagnosis of lung cancer. Methods: CEA, CA125, CYFRA21-1 in serum and pleural effusion of 60 patients with lung cancer and 52 patients with lung cancer were detected by chemiluminescence and electroluminescence. And neuron specific enolase (NSE) levels were detected. Results: CEA in pleural fluid of patients with lung cancer was 237.4 ± 209.1 ng / ml, CA125 was 234.0 ± 154.1 U / ml, NSE was 38.4 ± 26.5 ng / ml, CYFRA21-1 was 64.7 ± 61.8 ng / ml, which was significantly higher than that of the serum (P <0.01) and serum and pleural effusion in non-lung cancer patients (P <0.01). The sensitivity of the four joint tests in pleural effusion to lung cancer was 96.6%, while the corresponding four sera in the pleural fluid sensitivity to lung cancer was 92.3%. Conclusion: The combined detection of CEA, CA125, NSE and CYFRA21-1 in serum and pleural effusion is of great significance for the diagnosis of lung cancer.